PITTSBURGH, April 30 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL - News) today announced that the U.S. District Court for the District of Columbia issued a decision denying all requests for preliminary injunction related to Amlodipine Besylate Tablets and supporting the U.S. Food and Drug Administration's (FDA) position concerning Mylan's current status as the only approved ANDA for all strengths of this product. In the decision, the District Court confirmed the position taken by the FDA that all of the unapproved amlodipine besylate ANDAs are currently blocked from approval by pediatric exclusivity.
